

Global Late-Stage Oncology Drug Market Growth 2024-2030

<https://marketpublishers.com/r/G5B250588C53EN.html>

Date: June 2024

Pages: 107

Price: US\$ 3,660.00 (Single User License)

ID: G5B250588C53EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

A late-stage oncology drug refers to a medication or treatment that has advanced through the initial phases of clinical trials (phases I and II) and is now being tested in phase III clinical trials or is awaiting regulatory approval for marketing. These drugs are typically intended for the treatment of cancer in patients who have advanced disease or have not responded well to standard treatments. Late-stage oncology drugs undergo rigorous testing to assess their safety, efficacy, and potential side effects in larger groups of patients before they can be approved for use in clinical practice.

The global Late-Stage Oncology Drug market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Late-Stage Oncology Drug Industry Forecast" looks at past sales and reviews total world Late-Stage Oncology Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Late-Stage Oncology Drug sales for 2024 through 2030. With Late-Stage Oncology Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Late-Stage Oncology Drug industry.

This Insight Report provides a comprehensive analysis of the global Late-Stage Oncology Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on

Late-Stage Oncology Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Late-Stage Oncology Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Late-Stage Oncology Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Late-Stage Oncology Drug.

United States market for Late-Stage Oncology Drug is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Late-Stage Oncology Drug is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Late-Stage Oncology Drug is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Late-Stage Oncology Drug players cover Roche, Merck & Co, Bristol Myers, Pfizer, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Late-Stage Oncology Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Chemotherapy

Targeted Therapy

Immunotherapy

Hormonal Therapy

Others

Segmentation by Application:

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory or Lung Cancer

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Merck & Co

Bristol Myers

Pfizer

Novartis

AstraZeneca

Johnson & Johnson

Eli Lilly and Company

Sanofi

AbbVie

GSK

Amgen

Genentech

Daiichi Sankyo Group

Aveo Oncology

Key Questions Addressed in this Report

What is the 10-year outlook for the global Late-Stage Oncology Drug market?

What factors are driving Late-Stage Oncology Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Late-Stage Oncology Drug market opportunities vary by end market size?

How does Late-Stage Oncology Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Late-Stage Oncology Drug Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Late-Stage Oncology Drug by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Late-Stage Oncology Drug by Country/Region, 2019, 2023 & 2030
- 2.2 Late-Stage Oncology Drug Segment by Type
 - 2.2.1 Chemotherapy
 - 2.2.2 Targeted Therapy
 - 2.2.3 Immunotherapy
 - 2.2.4 Hormonal Therapy
 - 2.2.5 Others
- 2.3 Late-Stage Oncology Drug Sales by Type
 - 2.3.1 Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Late-Stage Oncology Drug Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Late-Stage Oncology Drug Sale Price by Type (2019-2024)
- 2.4 Late-Stage Oncology Drug Segment by Application
 - 2.4.1 Blood Cancer
 - 2.4.2 Breast Cancer
 - 2.4.3 Gastrointestinal Cancer
 - 2.4.4 Prostate Cancer
 - 2.4.5 Respiratory or Lung Cancer
 - 2.4.6 Other

2.5 Late-Stage Oncology Drug Sales by Application

2.5.1 Global Late-Stage Oncology Drug Sale Market Share by Application (2019-2024)

2.5.2 Global Late-Stage Oncology Drug Revenue and Market Share by Application (2019-2024)

2.5.3 Global Late-Stage Oncology Drug Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Late-Stage Oncology Drug Breakdown Data by Company

3.1.1 Global Late-Stage Oncology Drug Annual Sales by Company (2019-2024)

3.1.2 Global Late-Stage Oncology Drug Sales Market Share by Company (2019-2024)

3.2 Global Late-Stage Oncology Drug Annual Revenue by Company (2019-2024)

3.2.1 Global Late-Stage Oncology Drug Revenue by Company (2019-2024)

3.2.2 Global Late-Stage Oncology Drug Revenue Market Share by Company (2019-2024)

3.3 Global Late-Stage Oncology Drug Sale Price by Company

3.4 Key Manufacturers Late-Stage Oncology Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Late-Stage Oncology Drug Product Location Distribution

3.4.2 Players Late-Stage Oncology Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LATE-STAGE ONCOLOGY DRUG BY GEOGRAPHIC REGION

4.1 World Historic Late-Stage Oncology Drug Market Size by Geographic Region (2019-2024)

4.1.1 Global Late-Stage Oncology Drug Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Late-Stage Oncology Drug Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Late-Stage Oncology Drug Market Size by Country/Region (2019-2024)

4.2.1 Global Late-Stage Oncology Drug Annual Sales by Country/Region (2019-2024)

4.2.2 Global Late-Stage Oncology Drug Annual Revenue by Country/Region

(2019-2024)

4.3 Americas Late-Stage Oncology Drug Sales Growth

4.4 APAC Late-Stage Oncology Drug Sales Growth

4.5 Europe Late-Stage Oncology Drug Sales Growth

4.6 Middle East & Africa Late-Stage Oncology Drug Sales Growth

5 AMERICAS

5.1 Americas Late-Stage Oncology Drug Sales by Country

5.1.1 Americas Late-Stage Oncology Drug Sales by Country (2019-2024)

5.1.2 Americas Late-Stage Oncology Drug Revenue by Country (2019-2024)

5.2 Americas Late-Stage Oncology Drug Sales by Type (2019-2024)

5.3 Americas Late-Stage Oncology Drug Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Late-Stage Oncology Drug Sales by Region

6.1.1 APAC Late-Stage Oncology Drug Sales by Region (2019-2024)

6.1.2 APAC Late-Stage Oncology Drug Revenue by Region (2019-2024)

6.2 APAC Late-Stage Oncology Drug Sales by Type (2019-2024)

6.3 APAC Late-Stage Oncology Drug Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Late-Stage Oncology Drug by Country

7.1.1 Europe Late-Stage Oncology Drug Sales by Country (2019-2024)

7.1.2 Europe Late-Stage Oncology Drug Revenue by Country (2019-2024)

7.2 Europe Late-Stage Oncology Drug Sales by Type (2019-2024)

7.3 Europe Late-Stage Oncology Drug Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Late-Stage Oncology Drug by Country

8.1.1 Middle East & Africa Late-Stage Oncology Drug Sales by Country (2019-2024)

8.1.2 Middle East & Africa Late-Stage Oncology Drug Revenue by Country (2019-2024)

8.2 Middle East & Africa Late-Stage Oncology Drug Sales by Type (2019-2024)

8.3 Middle East & Africa Late-Stage Oncology Drug Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Late-Stage Oncology Drug

10.3 Manufacturing Process Analysis of Late-Stage Oncology Drug

10.4 Industry Chain Structure of Late-Stage Oncology Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Late-Stage Oncology Drug Distributors

11.3 Late-Stage Oncology Drug Customer

12 WORLD FORECAST REVIEW FOR LATE-STAGE ONCOLOGY DRUG BY GEOGRAPHIC REGION

12.1 Global Late-Stage Oncology Drug Market Size Forecast by Region

12.1.1 Global Late-Stage Oncology Drug Forecast by Region (2025-2030)

12.1.2 Global Late-Stage Oncology Drug Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Late-Stage Oncology Drug Forecast by Type (2025-2030)

12.7 Global Late-Stage Oncology Drug Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Roche

13.1.1 Roche Company Information

13.1.2 Roche Late-Stage Oncology Drug Product Portfolios and Specifications

13.1.3 Roche Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Roche Main Business Overview

13.1.5 Roche Latest Developments

13.2 Merck & Co

13.2.1 Merck & Co Company Information

13.2.2 Merck & Co Late-Stage Oncology Drug Product Portfolios and Specifications

13.2.3 Merck & Co Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Merck & Co Main Business Overview

13.2.5 Merck & Co Latest Developments

13.3 Bristol Myers

13.3.1 Bristol Myers Company Information

13.3.2 Bristol Myers Late-Stage Oncology Drug Product Portfolios and Specifications

13.3.3 Bristol Myers Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 Bristol Myers Main Business Overview

- 13.3.5 Bristol Myers Latest Developments
- 13.4 Pfizer
 - 13.4.1 Pfizer Company Information
 - 13.4.2 Pfizer Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.4.3 Pfizer Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Pfizer Main Business Overview
 - 13.4.5 Pfizer Latest Developments
- 13.5 Novartis
 - 13.5.1 Novartis Company Information
 - 13.5.2 Novartis Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.5.3 Novartis Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Novartis Main Business Overview
 - 13.5.5 Novartis Latest Developments
- 13.6 AstraZeneca
 - 13.6.1 AstraZeneca Company Information
 - 13.6.2 AstraZeneca Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.6.3 AstraZeneca Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 AstraZeneca Main Business Overview
 - 13.6.5 AstraZeneca Latest Developments
- 13.7 Johnson & Johnson
 - 13.7.1 Johnson & Johnson Company Information
 - 13.7.2 Johnson & Johnson Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.7.3 Johnson & Johnson Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Johnson & Johnson Main Business Overview
 - 13.7.5 Johnson & Johnson Latest Developments
- 13.8 Eli Lilly and Company
 - 13.8.1 Eli Lilly and Company Company Information
 - 13.8.2 Eli Lilly and Company Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.8.3 Eli Lilly and Company Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.8.4 Eli Lilly and Company Main Business Overview
 - 13.8.5 Eli Lilly and Company Latest Developments
- 13.9 Sanofi

- 13.9.1 Sanofi Company Information
- 13.9.2 Sanofi Late-Stage Oncology Drug Product Portfolios and Specifications
- 13.9.3 Sanofi Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.9.4 Sanofi Main Business Overview
- 13.9.5 Sanofi Latest Developments
- 13.10 AbbVie
 - 13.10.1 AbbVie Company Information
 - 13.10.2 AbbVie Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.10.3 AbbVie Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.10.4 AbbVie Main Business Overview
 - 13.10.5 AbbVie Latest Developments
- 13.11 GSK
 - 13.11.1 GSK Company Information
 - 13.11.2 GSK Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.11.3 GSK Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 GSK Main Business Overview
 - 13.11.5 GSK Latest Developments
- 13.12 Amgen
 - 13.12.1 Amgen Company Information
 - 13.12.2 Amgen Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.12.3 Amgen Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Amgen Main Business Overview
 - 13.12.5 Amgen Latest Developments
- 13.13 Genentech
 - 13.13.1 Genentech Company Information
 - 13.13.2 Genentech Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.13.3 Genentech Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.13.4 Genentech Main Business Overview
 - 13.13.5 Genentech Latest Developments
- 13.14 Daiichi Sankyo Group
 - 13.14.1 Daiichi Sankyo Group Company Information
 - 13.14.2 Daiichi Sankyo Group Late-Stage Oncology Drug Product Portfolios and Specifications
 - 13.14.3 Daiichi Sankyo Group Late-Stage Oncology Drug Sales, Revenue, Price and

Gross Margin (2019-2024)

13.14.4 Daiichi Sankyo Group Main Business Overview

13.14.5 Daiichi Sankyo Group Latest Developments

13.15 Aveo Oncology

13.15.1 Aveo Oncology Company Information

13.15.2 Aveo Oncology Late-Stage Oncology Drug Product Portfolios and Specifications

13.15.3 Aveo Oncology Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.15.4 Aveo Oncology Main Business Overview

13.15.5 Aveo Oncology Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Late-Stage Oncology Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Table 2. Late-Stage Oncology Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of Chemotherapy
- Table 4. Major Players of Targeted Therapy
- Table 5. Major Players of Immunotherapy
- Table 6. Major Players of Hormonal Therapy
- Table 7. Major Players of Others
- Table 8. Global Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
- Table 9. Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
- Table 10. Global Late-Stage Oncology Drug Revenue by Type (2019-2024) & (\$ million)
- Table 11. Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2024)
- Table 12. Global Late-Stage Oncology Drug Sale Price by Type (2019-2024) & (US\$/g)
- Table 13. Global Late-Stage Oncology Drug Sale by Application (2019-2024) & (kg)
- Table 14. Global Late-Stage Oncology Drug Sale Market Share by Application (2019-2024)
- Table 15. Global Late-Stage Oncology Drug Revenue by Application (2019-2024) & (\$ million)
- Table 16. Global Late-Stage Oncology Drug Revenue Market Share by Application (2019-2024)
- Table 17. Global Late-Stage Oncology Drug Sale Price by Application (2019-2024) & (US\$/g)
- Table 18. Global Late-Stage Oncology Drug Sales by Company (2019-2024) & (kg)
- Table 19. Global Late-Stage Oncology Drug Sales Market Share by Company (2019-2024)
- Table 20. Global Late-Stage Oncology Drug Revenue by Company (2019-2024) & (\$ millions)
- Table 21. Global Late-Stage Oncology Drug Revenue Market Share by Company (2019-2024)
- Table 22. Global Late-Stage Oncology Drug Sale Price by Company (2019-2024) & (US\$/g)
- Table 23. Key Manufacturers Late-Stage Oncology Drug Producing Area Distribution and Sales Area

- Table 24. Players Late-Stage Oncology Drug Products Offered
- Table 25. Late-Stage Oncology Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- Table 26. New Products and Potential Entrants
- Table 27. Market M&A Activity & Strategy
- Table 28. Global Late-Stage Oncology Drug Sales by Geographic Region (2019-2024) & (kg)
- Table 29. Global Late-Stage Oncology Drug Sales Market Share Geographic Region (2019-2024)
- Table 30. Global Late-Stage Oncology Drug Revenue by Geographic Region (2019-2024) & (\$ millions)
- Table 31. Global Late-Stage Oncology Drug Revenue Market Share by Geographic Region (2019-2024)
- Table 32. Global Late-Stage Oncology Drug Sales by Country/Region (2019-2024) & (kg)
- Table 33. Global Late-Stage Oncology Drug Sales Market Share by Country/Region (2019-2024)
- Table 34. Global Late-Stage Oncology Drug Revenue by Country/Region (2019-2024) & (\$ millions)
- Table 35. Global Late-Stage Oncology Drug Revenue Market Share by Country/Region (2019-2024)
- Table 36. Americas Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
- Table 37. Americas Late-Stage Oncology Drug Sales Market Share by Country (2019-2024)
- Table 38. Americas Late-Stage Oncology Drug Revenue by Country (2019-2024) & (\$ millions)
- Table 39. Americas Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
- Table 40. Americas Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
- Table 41. APAC Late-Stage Oncology Drug Sales by Region (2019-2024) & (kg)
- Table 42. APAC Late-Stage Oncology Drug Sales Market Share by Region (2019-2024)
- Table 43. APAC Late-Stage Oncology Drug Revenue by Region (2019-2024) & (\$ millions)
- Table 44. APAC Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
- Table 45. APAC Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
- Table 46. Europe Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
- Table 47. Europe Late-Stage Oncology Drug Revenue by Country (2019-2024) & (\$ millions)
- Table 48. Europe Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
- Table 49. Europe Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)

- Table 50. Middle East & Africa Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
- Table 51. Middle East & Africa Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
- Table 52. Middle East & Africa Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
- Table 53. Middle East & Africa Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
- Table 54. Key Market Drivers & Growth Opportunities of Late-Stage Oncology Drug
- Table 55. Key Market Challenges & Risks of Late-Stage Oncology Drug
- Table 56. Key Industry Trends of Late-Stage Oncology Drug
- Table 57. Late-Stage Oncology Drug Raw Material
- Table 58. Key Suppliers of Raw Materials
- Table 59. Late-Stage Oncology Drug Distributors List
- Table 60. Late-Stage Oncology Drug Customer List
- Table 61. Global Late-Stage Oncology Drug Sales Forecast by Region (2025-2030) & (kg)
- Table 62. Global Late-Stage Oncology Drug Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 63. Americas Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
- Table 64. Americas Late-Stage Oncology Drug Annual Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 65. APAC Late-Stage Oncology Drug Sales Forecast by Region (2025-2030) & (kg)
- Table 66. APAC Late-Stage Oncology Drug Annual Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 67. Europe Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
- Table 68. Europe Late-Stage Oncology Drug Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 69. Middle East & Africa Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
- Table 70. Middle East & Africa Late-Stage Oncology Drug Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 71. Global Late-Stage Oncology Drug Sales Forecast by Type (2025-2030) & (kg)
- Table 72. Global Late-Stage Oncology Drug Revenue Forecast by Type (2025-2030) & (\$ millions)
- Table 73. Global Late-Stage Oncology Drug Sales Forecast by Application (2025-2030)

& (kg)

Table 74. Global Late-Stage Oncology Drug Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 75. Roche Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 76. Roche Late-Stage Oncology Drug Product Portfolios and Specifications

Table 77. Roche Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 78. Roche Main Business

Table 79. Roche Latest Developments

Table 80. Merck & Co Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 81. Merck & Co Late-Stage Oncology Drug Product Portfolios and Specifications

Table 82. Merck & Co Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 83. Merck & Co Main Business

Table 84. Merck & Co Latest Developments

Table 85. Bristol Myers Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 86. Bristol Myers Late-Stage Oncology Drug Product Portfolios and Specifications

Table 87. Bristol Myers Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 88. Bristol Myers Main Business

Table 89. Bristol Myers Latest Developments

Table 90. Pfizer Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 91. Pfizer Late-Stage Oncology Drug Product Portfolios and Specifications

Table 92. Pfizer Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 93. Pfizer Main Business

Table 94. Pfizer Latest Developments

Table 95. Novartis Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 96. Novartis Late-Stage Oncology Drug Product Portfolios and Specifications

Table 97. Novartis Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 98. Novartis Main Business

Table 99. Novartis Latest Developments

Table 100. AstraZeneca Basic Information, Late-Stage Oncology Drug Manufacturing

Base, Sales Area and Its Competitors

Table 101. AstraZeneca Late-Stage Oncology Drug Product Portfolios and Specifications

Table 102. AstraZeneca Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 103. AstraZeneca Main Business

Table 104. AstraZeneca Latest Developments

Table 105. Johnson & Johnson Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 106. Johnson & Johnson Late-Stage Oncology Drug Product Portfolios and Specifications

Table 107. Johnson & Johnson Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 108. Johnson & Johnson Main Business

Table 109. Johnson & Johnson Latest Developments

Table 110. Eli Lilly and Company Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 111. Eli Lilly and Company Late-Stage Oncology Drug Product Portfolios and Specifications

Table 112. Eli Lilly and Company Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 113. Eli Lilly and Company Main Business

Table 114. Eli Lilly and Company Latest Developments

Table 115. Sanofi Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 116. Sanofi Late-Stage Oncology Drug Product Portfolios and Specifications

Table 117. Sanofi Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 118. Sanofi Main Business

Table 119. Sanofi Latest Developments

Table 120. AbbVie Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

Table 121. AbbVie Late-Stage Oncology Drug Product Portfolios and Specifications

Table 122. AbbVie Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)

Table 123. AbbVie Main Business

Table 124. AbbVie Latest Developments

Table 125. GSK Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors

- Table 126. GSK Late-Stage Oncology Drug Product Portfolios and Specifications
- Table 127. GSK Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)
- Table 128. GSK Main Business
- Table 129. GSK Latest Developments
- Table 130. Amgen Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
- Table 131. Amgen Late-Stage Oncology Drug Product Portfolios and Specifications
- Table 132. Amgen Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)
- Table 133. Amgen Main Business
- Table 134. Amgen Latest Developments
- Table 135. Genentech Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
- Table 136. Genentech Late-Stage Oncology Drug Product Portfolios and Specifications
- Table 137. Genentech Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)
- Table 138. Genentech Main Business
- Table 139. Genentech Latest Developments
- Table 140. Daiichi Sankyo Group Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
- Table 141. Daiichi Sankyo Group Late-Stage Oncology Drug Product Portfolios and Specifications
- Table 142. Daiichi Sankyo Group Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)
- Table 143. Daiichi Sankyo Group Main Business
- Table 144. Daiichi Sankyo Group Latest Developments
- Table 145. Aveo Oncology Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
- Table 146. Aveo Oncology Late-Stage Oncology Drug Product Portfolios and Specifications
- Table 147. Aveo Oncology Late-Stage Oncology Drug Sales (kg), Revenue (\$ Million), Price (US\$/g) and Gross Margin (2019-2024)
- Table 148. Aveo Oncology Main Business
- Table 149. Aveo Oncology Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Late-Stage Oncology Drug
- Figure 2. Late-Stage Oncology Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Late-Stage Oncology Drug Sales Growth Rate 2019-2030 (kg)
- Figure 7. Global Late-Stage Oncology Drug Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Late-Stage Oncology Drug Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Late-Stage Oncology Drug Sales Market Share by Country/Region (2023)
- Figure 10. Late-Stage Oncology Drug Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of Chemotherapy
- Figure 12. Product Picture of Targeted Therapy
- Figure 13. Product Picture of Immunotherapy
- Figure 14. Product Picture of Hormonal Therapy
- Figure 15. Product Picture of Others
- Figure 16. Global Late-Stage Oncology Drug Sales Market Share by Type in 2023
- Figure 17. Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2024)
- Figure 18. Late-Stage Oncology Drug Consumed in Blood Cancer
- Figure 19. Global Late-Stage Oncology Drug Market: Blood Cancer (2019-2024) & (kg)
- Figure 20. Late-Stage Oncology Drug Consumed in Breast Cancer
- Figure 21. Global Late-Stage Oncology Drug Market: Breast Cancer (2019-2024) & (kg)
- Figure 22. Late-Stage Oncology Drug Consumed in Gastrointestinal Cancer
- Figure 23. Global Late-Stage Oncology Drug Market: Gastrointestinal Cancer (2019-2024) & (kg)
- Figure 24. Late-Stage Oncology Drug Consumed in Prostate Cancer
- Figure 25. Global Late-Stage Oncology Drug Market: Prostate Cancer (2019-2024) & (kg)
- Figure 26. Late-Stage Oncology Drug Consumed in Respiratory or Lung Cancer
- Figure 27. Global Late-Stage Oncology Drug Market: Respiratory or Lung Cancer (2019-2024) & (kg)
- Figure 28. Late-Stage Oncology Drug Consumed in Other

- Figure 29. Global Late-Stage Oncology Drug Market: Other (2019-2024) & (kg)
- Figure 30. Global Late-Stage Oncology Drug Sale Market Share by Application (2023)
- Figure 31. Global Late-Stage Oncology Drug Revenue Market Share by Application in 2023
- Figure 32. Late-Stage Oncology Drug Sales by Company in 2023 (kg)
- Figure 33. Global Late-Stage Oncology Drug Sales Market Share by Company in 2023
- Figure 34. Late-Stage Oncology Drug Revenue by Company in 2023 (\$ millions)
- Figure 35. Global Late-Stage Oncology Drug Revenue Market Share by Company in 2023
- Figure 36. Global Late-Stage Oncology Drug Sales Market Share by Geographic Region (2019-2024)
- Figure 37. Global Late-Stage Oncology Drug Revenue Market Share by Geographic Region in 2023
- Figure 38. Americas Late-Stage Oncology Drug Sales 2019-2024 (kg)
- Figure 39. Americas Late-Stage Oncology Drug Revenue 2019-2024 (\$ millions)
- Figure 40. APAC Late-Stage Oncology Drug Sales 2019-2024 (kg)
- Figure 41. APAC Late-Stage Oncology Drug Revenue 2019-2024 (\$ millions)
- Figure 42. Europe Late-Stage Oncology Drug Sales 2019-2024 (kg)
- Figure 43. Europe Late-Stage Oncology Drug Revenue 2019-2024 (\$ millions)
- Figure 44. Middle East & Africa Late-Stage Oncology Drug Sales 2019-2024 (kg)
- Figure 45. Middle East & Africa Late-Stage Oncology Drug Revenue 2019-2024 (\$ millions)
- Figure 46. Americas Late-Stage Oncology Drug Sales Market Share by Country in 2023
- Figure 47. Americas Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
- Figure 48. Americas Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
- Figure 49. Americas Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
- Figure 50. United States Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)
- Figure 51. Canada Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)
- Figure 52. Mexico Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)
- Figure 53. Brazil Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)
- Figure 54. APAC Late-Stage Oncology Drug Sales Market Share by Region in 2023
- Figure 55. APAC Late-Stage Oncology Drug Revenue Market Share by Region (2019-2024)
- Figure 56. APAC Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
- Figure 57. APAC Late-Stage Oncology Drug Sales Market Share by Application

(2019-2024)

Figure 58. China Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 59. Japan Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 60. South Korea Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 61. Southeast Asia Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 62. India Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 63. Australia Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 64. China Taiwan Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 65. Europe Late-Stage Oncology Drug Sales Market Share by Country in 2023

Figure 66. Europe Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)

Figure 67. Europe Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)

Figure 68. Europe Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)

Figure 69. Germany Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 70. France Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 71. UK Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 72. Italy Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 73. Russia Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 74. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Country (2019-2024)

Figure 75. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)

Figure 76. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)

Figure 77. Egypt Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 78. South Africa Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 79. Israel Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 80. Turkey Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 81. GCC Countries Late-Stage Oncology Drug Revenue Growth 2019-2024 (\$ millions)

Figure 82. Manufacturing Cost Structure Analysis of Late-Stage Oncology Drug in 2023

Figure 83. Manufacturing Process Analysis of Late-Stage Oncology Drug

Figure 84. Industry Chain Structure of Late-Stage Oncology Drug

Figure 85. Channels of Distribution

Figure 86. Global Late-Stage Oncology Drug Sales Market Forecast by Region (2025-2030)

Figure 87. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Region (2025-2030)

Figure 88. Global Late-Stage Oncology Drug Sales Market Share Forecast by Type (2025-2030)

Figure 89. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Type (2025-2030)

Figure 90. Global Late-Stage Oncology Drug Sales Market Share Forecast by Application (2025-2030)

Figure 91. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Late-Stage Oncology Drug Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G5B250588C53EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5B250588C53EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970